TRPM-2 antisense therapy
US9074209B2 · kind B2 · utility
0Cited by
33References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 16, 2013 |
| Grant date | Jul 7, 2015 |
| Priority date | — |
| Expiry date | Sep 16, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/346
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for treating an individual suffering from a cancer comprising administering to the individual i) a chemotherapeutic agent, and ii) one antisense oligonucleotide having nucleotides in the sequence set forth in Seq. ID No. 4 and which antisense oligonucleotide has a phosphorothioate modification that increases the stability thereof in vivo, wherein the cancer expresses testosterone-repressed prostate message-2 (TRPM-2), thereby treating said individual.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.